Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial

[1]  Sunita Ghosh,et al.  Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung Cancer , 2017, American journal of clinical oncology.

[2]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[3]  N. O'Rourke,et al.  SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. , 2014, European journal of cancer.

[4]  J. Greenland,et al.  Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25. , 2014, Journal of the National Cancer Institute.

[5]  Wanqing Chen,et al.  Report of cancer incidence and mortality in China, 2010. , 2014, Annals of translational medicine.

[6]  Baosheng Li,et al.  Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy , 2014, Radiation oncology.

[7]  C. Faivre-Finn,et al.  How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer? , 2014, Lung cancer.

[8]  Pranshu Mohindra,et al.  Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Talamini,et al.  Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase i, docetaxel dose-escalation study, with hypofractionated radiation regimen , 2013, BMC Cancer.

[10]  S. Harden,et al.  Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Qiang Lin,et al.  Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial , 2013, Radiation oncology.

[12]  Joe Y. Chang,et al.  Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. , 2013, International journal of radiation oncology, biology, physics.

[13]  R. Swindell,et al.  The largest UK single centre series using hypofractionated radical radiotherapy for NSCLC in the very elderly. , 2013, Lung cancer.

[14]  H. Pyo,et al.  Hypofractionated Three-Dimensional Conformal Radiation Therapy Alone for Centrally Located cT1-3N0 Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  A. Maráz,et al.  Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer. , 2013, Anticancer research.

[16]  Henk Huizenga,et al.  Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial. , 2012, International journal of radiation oncology, biology, physics.

[17]  Adam P Dicker,et al.  Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. , 2012, International journal of radiation oncology, biology, physics.

[18]  Steven H. Lin,et al.  Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer , 2012, Radiation oncology.

[19]  G. Jiang,et al.  A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[21]  K. Tournel,et al.  Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy. , 2010, International journal of radiation oncology, biology, physics.

[22]  K. Mystakidou,et al.  Hypofractionated radiotherapy in non small cell lung cancer: a review of the current literature. , 2010, Reviews on recent clinical trials.

[23]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Philippe Lambin,et al.  Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Joseph O. Deasy,et al.  Radiation dose-volume effects in the esophagus. , 2010, International journal of radiation oncology, biology, physics.

[26]  T. Kimura,et al.  Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer , 2009, International Journal of Clinical Oncology.

[27]  O. Holmberg,et al.  Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  K. Bujko,et al.  Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  M. Leitch,et al.  Oesophageal toxicity and hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

[30]  H Jaradat,et al.  Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study , 2008, Technology in cancer research & treatment.

[31]  P. Lambin,et al.  Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. , 2008, International journal of radiation oncology, biology, physics.

[32]  P. Lambin,et al.  Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. , 2008, International journal of radiation oncology, biology, physics.

[33]  W. De Neve,et al.  Modern radiotherapy as part of combined modality treatment in locally advanced non-small cell lung cancer: present status and future prospects. , 2008, The oncologist.

[34]  Demosthenes Bouros,et al.  Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma. , 2007, Anticancer research.

[35]  J. Aerts,et al.  Radiation Oncology Bronchiolitis Obliterans Organizing Pneumonia (boop) after Thoracic Radiotherapy for Breast Carcinoma , 2022 .

[36]  T. Vuong,et al.  Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer , 2006, Radiation oncology.

[37]  R. T. Ten Haken,et al.  High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. , 2005, International journal of radiation oncology, biology, physics.

[38]  Jose Belderbos,et al.  Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  M. Machtay,et al.  Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer. , 2005, Seminars in oncology.

[40]  J. Lester,et al.  CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. , 2004, Lung cancer.

[41]  J. Fowler,et al.  Reduction in Radiation Dose to Lung and Other Normal Tissues Using Helical Tomotherapy to Treat Lung Cancer, in Comparison to Conventional Field Arrangements , 2003, American journal of clinical oncology.

[42]  Jeffrey D Bradley,et al.  Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[43]  M. Socinski,et al.  High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. , 2002, International journal of radiation oncology, biology, physics.

[44]  W. Curran,et al.  Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. , 2000, International journal of radiation oncology, biology, physics.

[45]  H. Bartelink,et al.  Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. , 2000, European journal of cancer.

[46]  A Harvey,et al.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[47]  P. Maguire,et al.  Clinical and dosimetric predictors of radiation-induced esophageal toxicity. , 1999, International journal of radiation oncology, biology, physics.

[48]  J. Herndon,et al.  Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. , 1996, Journal of the National Cancer Institute.

[49]  J. Damilakis,et al.  The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. , 1996, International journal of radiation oncology, biology, physics.

[50]  Phase ii Study of Accelerated Hypofractionated three-Dimensional conformal radiotherapy for Stage t 1-3 N 0 M 0 Non – Small cell lung cancer : Ncic ctG Br , 2014 .

[51]  R. Zheng,et al.  Report of Cancer Incidence and Mortality in China,2009 , 2013 .

[52]  Benjamin Movsas,et al.  Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. , 2012, International journal of radiation oncology, biology, physics.

[53]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[54]  Susan Westlake,et al.  Report: Cancer incidence and mortality , 2008 .

[55]  G. Giaccone,et al.  Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). , 2007, European journal of cancer.

[56]  E. Glatstein.  High-Dose Radiation Improved Local Tumor Control and Overall Survival in Patients With Inoperable/Unresectable Non–Small-Cell Lung Cancer: Long-term Results of a Radiation Dose Escalation Study , 2007 .

[57]  A. Colevas,et al.  The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  J. M. Taylor,et al.  The hazard of accelerated tumor clonogen repopulation during radiotherapy. , 1988, Acta oncologica.